Drugs / BR1019-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06226727 | Feb → Mar 2024 | essential hypertension, type 2 diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05875259 | May → Jun 2023 | hypertensive disorder, type 2 diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR1019-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06226727 ↗ |